G-11 is a novel trifluoromethyl-substituted pyrazole N-nucleoside showing strong and selective antiproliferative activities against various hematological and solid tumor cell lines.

G-11 induces cellular differentiation of the promyelocytic leukemia HL-60 cells to monocyte/macrophage and granulocyte.

G-11 inhibits the induced activation of the oncogenic kinase FLT3 (FMS-like tyrosine kinase 3, CD135), and thereby promotes differentiation of HL-60 cells.

In addition to the wild-type FLT3, G-11 also inhibits the constitutively active mutant type of FLT3 containing internal tandem repeats mutations (ITD).

Molecular Modeling studies show that G-11 docks within the ATP binding pocket of FLT3 in a comparable manner to the anticancer drug quizartinib, thus providing additional evidence supporting the development of G-11 as an anticancer agent for relapse free therapeutic strategies of AML patients.